Burning Rock Biotech Limited (BNR)
BNR trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/0001193125-26-183377-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BNR on Nasdaq |
| Sector | Health Care |
| Industry | Medical Specialities |
| Country | China |
| IPO year | 2020 |
| SEC CIK | 0001792267 |
| SEC industry code | Services-Medical Laboratories |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $77.2M |
| Net income | -$7.9M |
| Operating income | -$7.8M |
| Net margin | -10.3% |
| Operating margin | -10.2% |
| Revenue growth | +9.2% |
| Cash | $68.4M |
| Total assets | $117.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-28 |
| Cash and burn | $68.4M cash; operating cash flow -$1.0M a quarter. | Report 2025-12-31 |
| Shares outstanding | 10,583,450 (2025-12-31); 10,800,700 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-05-15 | Source 2024-05-15 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young Hua Ming LLP, Shanghai, China | PCAOB Form AP 2026-05-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $11.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $77.2M | -$7.9M | -$4.1M | $68.4M | $243K | $77.2M | 20-F 2026-04-28 |
| FY 2024 2024-12-31 | $70.7M | -$47.5M | -$12.6M | $71.2M | No debt tags | $70.7M | 20-F 2025-04-29 |
| FY 2023 2023-12-31 | $75.7M | -$92.1M | -$36.0M | $86.6M | No debt tags | $75.7M | 20-F 2024-04-29 |
| FY 2022 2022-12-31 | $81.7M | -$140.8M | -$66.2M | $131.3M | $0 | $81.7M | 20-F 2023-04-20 |
| FY 2021 2021-12-31 | $79.7M | -$125.0M | -$75.0M | $224.6M | $372K | $79.7M | 20-F 2022-04-29 |
| FY 2020 2020-12-31 | $65.9M | -$62.4M | -$11.3M | $290.5M | $1.1M | $65.9M | 20-F 2021-03-23 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-09-18 |
| Latest annual report FORM 20-F | 20-F | 2026-04-28 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-09-10 |
Source: SEC EDGAR submissions feed, 169 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.0% |
| 1 month | -11.4% |
| 3 months | +43.1% |
| Year to date | -34.0% |
| 1 year | +17.4% |
| From 52-week high | -67.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical Specialities
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLSI | TriSalus Life Sciences Inc. | $2.27 | -6.58% | $140.1M |
| KEQU | Kewaunee Scientific Corporation | $35.05 | -1.81% | $101.5M |
| BDSX | Biodesix Inc. | $9.00 | -8.91% | $99.8M |
| XGN | Exagen Inc. | $3.77 | -8.72% | $96.2M |
| SERA | Sera Prognostics Inc. | $1.94 | -3.48% | $77.2M |
| YDES | YD Bio Limited | $4.83 | -1.02% | $342.1M |
| FLGT | Fulgent Genetics Inc. | $24.07 | -2.37% | $672.6M |
| CSTL | Castle Biosciences Inc. | $32.75 | -3.08% | $1.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier